Frontiers in Pharmacology | Neuropharmacology

Original Research

Accepted on 16 Apr 2025

Administration of chiglitazar reverses chronic stress-induced depressive-like symptoms in mice via activation of hippocampal PPARα and BDNF

in Neuropharmacology

Jiu-Jian Zhou
Jie Zhao
Shang-Yan Gao
Yuan-Yuan Gao
Cheng Chen
Yi Ding
Zhonghua Wu
Pu-jian Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1587399

Mini Review

Accepted on 16 Apr 2025

Trace amine-associated receptors as potential targets for the treatment of anxiety and depression

in Neuropharmacology

Zelong Li
Luoting Wan
Jing Dong
Jinquan Li
Jianfeng Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1598048

Review

Published on 16 Apr 2025

Ginsenoside Rg1 in Parkinson’s disease: from basic research to clinical applications

in Neuropharmacology

Qianyan Wang
Lei Wei
Guanghui Chen
Qiang Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1490480

104 views

Systematic Review

Published on 16 Apr 2025

Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer’s disease

in Neuropharmacology

Haoyang Wang
Junying Pan
Mingming Zhang
Zengde Tan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1599048

190 views

Original Research

Published on 16 Apr 2025

Significant hindlimb static weight-bearing asymmetry persists for 40-weeks in a longitudinal study in two widely used rat models of surgically induced osteoarthritis knee pain

in Neuropharmacology

A. Kuo
A. Raboczyj
J. R. Nicholson
L. Corradini
M. T. Smith

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1560265

116 views

Review

Accepted on 15 Apr 2025

Potential Therapeutic Targets for Ischemic Stroke in Pre-clinical Studies: Epigenetic-Modifying Enzymes DNMT/TET and HAT/HDAC

in Neuropharmacology

Yurou Guo
Jing Li
Xiaodan Liu
Huang Ding
Wei Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1571276

103 views

Mini Review

Accepted on 14 Apr 2025

The role of glutamate dehydrogenase in the ageing brain

in Neuropharmacology

Tao Zhou
Haichuan Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1586655

Review

Accepted on 14 Apr 2025

Current insights and prospects for the pathogenesis and treatment of clinical manifestations associated with Down syndrome through neurotransmitter, inflammatory, and oxidative stress pathways

in Neuropharmacology

Fawaz Alasmari
Ashfaq Ahmad
Sary Alsanea
Alaa Hammad
Walid Al-Qerem

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1592277

Systematic Review

Accepted on 14 Apr 2025

Effectiveness and Safety of Single Anti-Seizure Medication as Adjunctive Therapy for Drug-Resistant Focal Epilepsy based on Network Meta-Analysis

in Neuropharmacology

Nian-Jia Deng
Zhixin Zhang
Chen-Yang Xian-Yu
Yu-Ting Tao
Yu-Tong Ma
Hui-Jun Li
Teng-Yu Gao
Xin Liu
Jie Luo
Chao Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1500475

Editorial

Accepted on 14 Apr 2025

Editorial: "The interplay between chronic pain and affective-cognitive alterations: shared neural mechanisms, circuits, and treatment"

in Neuropharmacology

Luca Posa
Danilo De Gregorio
Kelly Smart
Serena Boccella

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1605670

Original Research

Accepted on 14 Apr 2025

Region-specific neuroprotective effects of meldonium pretreatment in two models of sepsis-associated encephalopathy

in Neuropharmacology

Aleksandra Ružičić
Tijana Srdić
Katarina Bobić
Dunja Drakulić
Filip Veljkovic
Ana Todorović
Sinisa Djurasevic
Iva Lakic

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1588831

Review

Published on 14 Apr 2025

Integrative approaches to depression in end-stage renal disease: insights into mechanisms, impacts, and pharmacological strategies

in Neuropharmacology

Cheng Yuan
Fengpei Chang
Hongfu Zhai
Jiayin Du
Danqin Lu
Haoli Ma
Xiaoyan Wu
Ping Gao
Lihua Ni

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1559038

252 views

Editorial

Published on 14 Apr 2025

Editorial: Exploring the key targets and compounds that manipulate brain neurocircuits against mental disorders and psychiatric volume II

in Neuropharmacology

Weijie Xie
Yuan Li
Song Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1601881

180 views

Original Research

Accepted on 11 Apr 2025

Multi-Target Neuroprotection by dl-PHPB in APP/PS1 Mice: a proteomic analysis

in Neuropharmacology

Yingni Sun
Guoliang Bai
Kangmin Yang
Yong Feng
Hongmei Sun
Li Xian
Hongwei Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1554168

Original Research

Accepted on 11 Apr 2025

Loss of expression and function of Gβγ by GNB1 Encephalopathy-associated L95P mutation of Gβ 1 subunit

in Neuropharmacology

Haritha Polagari Reddy
Tal Keren-Raifman
Galit Tabak
Nathan Dascal
Daniel Yakubovich

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1592012

Review

Accepted on 11 Apr 2025

Efficacy, Safety, and Tolerability of Soticlestat (TAK-935) as Adjunctive Therapy in Pediatric Patients with Dravet syndrome and Lennox-Gastaut syndrome: A Meta-analysis of 3 Randomized Controlled Trials

in Neuropharmacology

Zhang Lanlan
Jiang Nana
Wang Chengzhong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1586098

170 views